ACTINIUM PHARMACEUTICALS, INC. Employee Benefits and Share-based Compensation
ACTINIUM PHARMACEUTICALS, INC. (ATNM) reported Employee Benefits and Share-based Compensation of $1.75 million for the 3-month period ending 2014-03-31, per its 10-Q filed 2014-05-12.
Discontinued › Notes › Compensation Related Costs
us-gaap:EmployeeBenefitsAndShareBasedCompensation · last filed 2014-05-12
- ACTINIUM PHARMACEUTICALS, INC. employee benefits and share-based compensation for the quarter ending 2014-03-31 was $1.75M, a 1758.73% increase year-over-year.
- ACTINIUM PHARMACEUTICALS, INC. employee benefits and share-based compensation for the quarter ending 2013-12-31 was $373.44K, a 80.46% decline year-over-year.
- ACTINIUM PHARMACEUTICALS, INC. employee benefits and share-based compensation for the quarter ending 2013-09-30 was $95.97K, a 33.11% increase year-over-year.
- ACTINIUM PHARMACEUTICALS, INC. employee benefits and share-based compensation for the quarter ending 2013-06-30 was $94.20K, a 133.11% increase year-over-year.
- ACTINIUM PHARMACEUTICALS, INC. employee benefits and share-based compensation for fiscal 2013 was $657.81K, a 70.42% decline from fiscal 2012.
- ACTINIUM PHARMACEUTICALS, INC. employee benefits and share-based compensation for fiscal 2012 was $2.22M, a 2.33% increase from fiscal 2011.
- ACTINIUM PHARMACEUTICALS, INC. employee benefits and share-based compensation for fiscal 2011 was $2.17M.
| Period end | Employee Benefits and Share-based Compensation 3 month | Employee Benefits and Share-based Compensation 6 month | Employee Benefits and Share-based Compensation 9 month | Employee Benefits and Share-based Compensation 12 month | Employee Benefits and Share-based Compensation 151 month | Employee Benefits and Share-based Compensation 154 month | Employee Benefits and Share-based Compensation 157 month | Employee Benefits and Share-based Compensation 160 month | Employee Benefits and Share-based Compensation 163 month | Employee Benefits and Share-based Compensation 166 month |
|---|---|---|---|---|---|---|---|---|---|---|
| 2014-03-31 | $1.75M 10-Q · filed 2014-05-12 | $2.12M derived: sum of 2 quarters · filed 2014-05-12 | $2.22M derived: sum of 3 quarters · filed 2014-05-12 | $2.31M derived: sum of 4 quarters · filed 2014-05-12 | $8.46M 10-Q · filed 2014-05-12 | |||||
| 2013-12-31 | $373.44K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $469.41K derived: sum of 2 quarters · filed 2014-02-28 | $563.61K derived: sum of 3 quarters · filed 2014-02-28 | $657.81K 10-K · filed 2014-02-28 | $6.71M 10-K · filed 2014-02-28 | |||||
| 2013-09-30 | $95.97K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | $190.17K derived: sum of 2 quarters · filed 2013-11-14 | $284.37K 10-Q · filed 2013-11-14 | $2.20M derived: sum of 4 quarters · filed 2014-05-12 | $6.34M 10-Q · filed 2013-11-14 | |||||
| 2013-06-30 | $94.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-13 | $188.40K 10-Q · filed 2013-08-13 | $2.10M derived: sum of 3 quarters · filed 2014-05-12 | $2.17M derived: sum of 4 quarters · filed 2014-05-12 | $6.24M 10-Q · filed 2013-08-13 | |||||
| 2013-03-31 | $94.20K 10-Q · filed 2014-05-12 | $2.01M derived: sum of 2 quarters · filed 2014-05-12 | $2.08M derived: sum of 3 quarters · filed 2014-05-12 | $2.12M derived: sum of 4 quarters · filed 2014-05-12 | $6.15M 10-Q · filed 2013-05-15 | |||||
| 2012-12-31 | $1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $1.98M derived: sum of 2 quarters · filed 2014-02-28 | $2.02M derived: sum of 3 quarters · filed 2014-02-28 | $2.22M 10-K · filed 2014-02-28 | $6.05M 10-K · filed 2013-03-29 | |||||
| 2012-09-30 | $72.10K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-14 | $112.51K derived: sum of 2 quarters · filed 2013-11-14 | $312.50K 10-Q · filed 2013-11-14 | |||||||
| 2012-06-30 | $40.41K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-13 | $240.40K 10-Q · filed 2013-08-13 | ||||||||
| 2012-03-31 | $199.99K 10-Q · filed 2013-05-15 | |||||||||
| 2011-12-31 | $2.17M 10-K · filed 2013-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |